New hope for hepatitis delta: phase 3 trial of brelovitug launches

NCT ID NCT07298330

Ongoing Disease control Sponsor: Mirum Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This Phase 3 trial tests a drug called brelovitug (BJT-778) in 80 people with chronic hepatitis delta, a serious liver infection. Participants receive either brelovitug or delayed treatment to see if the drug can lower virus levels and improve liver enzyme counts. The study is recruiting now and aims to find a safer, more effective way to manage this disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Brelovitug (also called BJT-778), a drug given as a shot under the skin
What this could lead to: If it works, this could offer a new treatment option to control hepatitis delta virus and reduce liver damage, potentially preventing progression to cirrhosis or liver failure.
What could go wrong: This is still an early Phase 3 trial with only 80 participants, so results may not apply to everyone. The drug may cause side effects, and it is not a cure—patients may need ongoing treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis D virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS D INFECTION

Contacts and locations

Locations

Acibadem City Clinic University Multiprofile Hospital for Active Treatment Tokuda

Sofia, 1407, Bulgaria
Aga Khan University & Hospital

Karachi, Karachi, 74800, Pakistan
Alliance Clinical, Las Vegas

Las Vegas, Nevada, 89019, United States
Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases

Budapest, H-1097, Hungary
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Denver Health Medical Center

Denver, Colorado, 80204, United States
Diakori LLC

Tbilisi, 0159, Georgia
E-Da Hospital

Kaohsiung City, 82445, Taiwan
Erasme Hospital

Brussels, Belgium
Fejer County St. Gyorgy University Teaching Hospital

Székesfehérvár, H-8000, Hungary
HaEmek Medical Center

Haifa, 3296043, Israel
Hospital Service LTD

Kutaisi, 4608, Georgia
JSC T. Tsertsvadze Infectious Diseases, AIDS and Clinical Immunology Research Center

Tbilisi, 0159, Georgia
Kaiser Permanente Medical Center

Sacramento, California, 95661, United States
Kaohsiung Medical University Chung-Ho Memorial Hospital

Kaohsiung City, 807377, Taiwan
LTD Academician Vakhtang Bochorishvili Clinic

Tbilisi, 0160, Georgia
Limited Liability Company "Medical Center Health and Rehabilitation "100 Percent Life"

Poltava, 36000, Ukraine
National Taiwan University Hospital

Taipei, 100225, Taiwan
Prime Clinical Research Inc

Mansfield, Texas, 76063, United States
Public Non-Profit Enterprise "Central City Hospital" of Rivne City Council

Rivne, 33018, Ukraine
Quest Clinical Research

San Francisco, California, 94115, United States
Research Institute of Virology of the Republic of Uzbekistan

Tashkent, 100194, Uzbekistan
Soroka University Medical Center

Beersheba, 8410101, Israel
University Hospital Antwerp (UZA)

Edegem, Belgium
University Hospital Center Sart-Tilman

Liège, Belgium
University of California, Davis

Davis, California, 95616, United States
University of Utah

Salt Lake City, Utah, 84132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.